Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2020; 12(12): 1228-1238
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1228
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1228
Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
Guan Huei Lee, Wai Mun Loo, Calvin Jianyi Koh, Juanda Leo Hartono, Mark Muthiah, Kieron Lim, Poh Seng Tan, Yin Mei Lee, Seng Gee Lim, Yock Young Dan, Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore 119228, Singapore
Guan Huei Lee, Wah Wah Phyo, Seng Gee Lim, Yock Young Dan, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Raymond Kwok, Taufique Ahmed, Department of Medicine, Khoo Teck Puat Hospital, Singapore 768828, Singapore
Asim Shabbir, Jimmy So, Department of Surgery, National University Health System, Singapore 119228, Singapore
Author contributions: Lee GH was involved in the conception and design of the study, data collection and analysis, drafting and revision of the manuscript; Phyo WW was involved in the data collection and analysis; Loo WM was involved in the drafting and revision of the manuscript; Kwok R, Ahmed T, Shabbir A, So J, Koh CJ, Hartono JL, Muthiah M, Lim K, Tan PS, Lee YM, Lim SG, and Dan YY contributed to the data collection and revision of the manuscript.
Supported by National University Health System , No. NUHSRO/2013/226/CRG/08 .
Institutional review board statement: The study was approved by the Institutional Review Board.
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: The authors declare that there is no conflict of interest.
Data sharing statement: No additional data available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guan Huei Lee, MBBS, PhD, Doctor, Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Singapore 119228, Singapore. mdcleegh@nus.edu.sg
Received: July 7, 2020
Peer-review started: July 9, 2020
First decision: September 11, 2020
Revised: September 28, 2020
Accepted: October 15, 2020
Article in press: October 15, 2020
Published online: December 27, 2020
Peer-review started: July 9, 2020
First decision: September 11, 2020
Revised: September 28, 2020
Accepted: October 15, 2020
Article in press: October 15, 2020
Published online: December 27, 2020
Core Tip
Core Tip: A number of genetic variations (known as single nucleotide polymorphism, SNPs) are reportedly associated with metabolic dysfunction-associated fatty liver disease (MAFLD), mostly by studies from Europe and America. This study examined 10 of the most important SNPs in a Chinese population in Singapore, and found that 1 such variation, the PNPLA3 GG variation, is strongly linked to MAFLD, whereas the rest are not significantly associated. PNPLA3, together with high triglyceride and elevated body mass index, are found to be independent, strong predictors of MAFLD.